SITC Cancer Immunotherapy Guideline News

In accordance with the Institute of Medicine’s Standards for Developing Trustworthy Clinical Practice Guidelines (CPGs), SITC CPGs undergo periodic evaluation to assess if new evidence necessitates modifications to recommendations, ...
0 comments
In accordance with the Institute of Medicine’s Standards for Developing Trustworthy Clinical Practice Guidelines (CPGs), SITC CPGs undergo periodic evaluation to assess if new evidence necessitates modifications to recommendations, ...
0 comments
In accordance with the Institute of Medicine’s Standards for Developing Trustworthy Clinical Practice Guidelines (CPGs), SITC CPGs undergo periodic evaluation to assess if new evidence necessitates modifications to recommendations, ...
0 comments
" Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer " originally published in the Journal for ImmunoTherapy of Cancer (JITC) on July 28, ...
0 comments
On behalf of the Society for Immunotherapy of Cancer (SITC) and the SITC Melanoma Guideline Expert Panel, we are pleased to announce the publication of SITC’s Melanoma Clinical Practice Guideline (CPG), version 3.0. This ...
0 comments
To address new, practice-changing data, "Addendum 1: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma" published in Journal for ImmunoTherapy ...
0 comments
On behalf of the Society for Immunotherapy of Cancer (SITC) and the SITC Gynecologic Cancer Immunotherapy Guideline Expert Panel, we are pleased to announce the publication of SITC’s Gynecologic Cancer Clinical Practice ...
0 comments
SITC is pleased to announce the publication of our newest guideline, " Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer. " Clinicians ...
0 comments
The Society for Immunotherapy of Cancer (SITC) Melanoma Immunotherapy Guideline Expert Panel is pleased to invite public comment on the draft clinical practice guideline (CPG) “Society for Immunotherapy of Cancer (SITC) clinical ...
0 comments
The Society for Immunotherapy of Cancer (SITC) is pleased to invite public comment on two new draft clinical practice guidelines (CPGs): “Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy ...
0 comments
The Society for Immunotherapy of Cancer (SITC) is currently recruiting practices for clinician-level testing of the draft quality measure: Positive PD-L1 Biomarker Expression Test Result Prior to First-Line Immune Checkpoint ...
0 comments
New interactive tools have been developed and integrated into the SITC CPG Mobile App for two of SITC’s guidelines that published in 2022. An overview of the guideline content as well as a highlight of the new tools and ...
0 comments
Previously published guidelines have new and updated content available only in the app. Below is an overview of the guidelines for which updates are available. A full description of the event that prompted the update as well ...
0 comments
SITC is pleased to announce the publication of our newest guideline, "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer." Clinicians will ...
0 comments
SITC is pleased to announce the publication of our newest guideline, " Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma . " This ...
0 comments
SITC is pleased to announce a new educational offering for the society’s clinical practice guidelines – SITC’s Cancer Immunotherapy Guidelines Mini Modules. Designed for practitioners with a desire to learn but with limited ...
0 comments
SITC’s Cancer Immunotherapy Guidelines Webinars connect clinicians with leading experts in the field and provide education about the evidence- and consensus-based recommendations in the clinical practice guidelines. On-demand ...
0 comments
The SITC Multiple Myeloma Expert Panel has updated the guidelines content and recommendations based on the November 30, 2021 FDA approval of daratumumab in combination with carfilzomib and dexamethasone (D-Kd) for adult patients ...
0 comments
The new hepatocellular carcinoma immunotherapy treatment algorithm was derived from the expert panel recommendations in the published SITC clinical practice guideline . This algorithm, available only in the free SITC ...
0 comments
On August 27, 2021, the indication for atezolizumab in combination with nab-paclitaxel as treatment for patients with triple-negative breast cancer (TNBC) whose tumors express PD-L1 was voluntarily withdrawn by the manufacturer. ...
0 comments